Allurion Technologies Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 2.86, above the company average. This is a clear sign of healthy business climate in the Medical Equipment & Supplies industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Allurion Technologies Inc in Mar 31 2026 quarter, has decreased to 128 days, compared to 138 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 518 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 3415 to 3557.

What is Receivable Turnover Ratio?
What is Allurion Technologies Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALUR Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-58.18 %	-44.62 %	-59.91 %	-56.22 %	-48.58 %
Y / Y Revenue Change	-42.9 %	-42.95 %	-54.92 %	-69.26 %	-41.79 %
Receivable Turnover Ratio (TTM)	2.86	2.64	2.75	2.59	2.87
ALUR's Total Ranking	# 3557	# 3415	# 3031	# 1511	# 3110
Accounts Receivable average collection period days	127	138	133	141	127
Seq. Receivable Change	-12.05 %	-0.8 %	-31.89 %	-29.62 %	16.47 %
Seq. Revenue Change	-20.93 %	61.76 %	-31.81 %	-34.53 %	-21 %

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 176
Healthcare Sector	# 519
Overall Market	# 3557

Receivable Turnover Ratio Statistics
High	Average	Low
3.28	2.76	1.87
(Sep 30 2024)		(Jun 30 2023)

ALUR Company Profile • Back to ALUR Efficiency Comparisons • Compare ALUR Receivables Turnover Ratio to its Competitors

Financial Statements
Allurion Technologies Inc 's Accounts Receivable	$ 3 Millions	Visit ALUR's Balance sheet
Allurion Technologies Inc 's Sales TTM	$ 12 Millions	Visit ALUR's Income Statement
Sources of ALUR's Revenues		Visit ALUR's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ALUR's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ALUR's Growth Rates	ALUR's Roa	ALUR's Inventory Turnover Ratio	ALUR's Dividend Comparisons
ALUR's Profitability Ratios	ALUR's Roi	ALUR's Asset Turnover Ratio	ALUR's Dividend Growth
ALUR's Valuation Ratios	ALUR's Roe	ALUR's Financial Strength Ratios	ALUR's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
X4 Pharmaceuticals Inc	9.69	$ 9.014 Millions	$ 0.931 Millions
Septerna Inc	9.64	$ 72.255 Millions	$ 7.499 Millions
Encompass Health Corporation	9.63	$ 6,066.400 Millions	$ 629.625 Millions
Biolife Solutions Inc	9.51	$ 99.673 Millions	$ 10.478 Millions
Biofrontera Inc	9.49	$ 42.983 Millions	$ 4.530 Millions
United Therapeutics Corporation	9.47	$ 3,169.800 Millions	$ 334.800 Millions
Tandem Diabetes Care Inc	9.34	$ 1,023.420 Millions	$ 109.550 Millions
Sunshine Biopharma Inc	9.33	$ 35.493 Millions	$ 3.804 Millions
The Oncology Institute Inc	9.30	$ 545.764 Millions	$ 58.671 Millions
The Pennant Group Inc	9.28	$ 1,023.227 Millions	$ 110.305 Millions
Enanta Pharmaceuticals Inc	9.26	$ 69.213 Millions	$ 7.477 Millions
Volitionrx Limited	9.23	$ 2.466 Millions	$ 0.267 Millions
Lucid Diagnostics Inc	9.11	$ 5.134 Millions	$ 0.564 Millions
Soleno Therapeutics Inc	9.09	$ 285.008 Millions	$ 31.369 Millions
Zomedica Corp	9.07	$ 34.660 Millions	$ 3.820 Millions
Dariohealth Corp	9.03	$ 20.983 Millions	$ 2.324 Millions
Harmony Biosciences Holdings inc	9.02	$ 899.247 Millions	$ 99.660 Millions
Tactile Systems Technology Inc	9.01	$ 343.414 Millions	$ 38.110 Millions
Ardent Health Inc	8.99	$ 6,428.975 Millions	$ 715.036 Millions
Sanuwave Health Inc	8.91	$ 44.328 Millions	$ 4.973 Millions
Biocryst Pharmaceuticals Inc	8.89	$ 885.716 Millions	$ 99.648 Millions
Madrigal Pharmaceuticals Inc	8.81	$ 1,132.490 Millions	$ 128.587 Millions
Inogen Inc	8.80	$ 351.497 Millions	$ 39.926 Millions
Grail Inc	8.77	$ 156.120 Millions	$ 17.809 Millions
Eyepoint Inc	8.76	$ 7.614 Millions	$ 0.869 Millions
Scientific Industries Inc	8.65	$ 6.588 Millions	$ 0.761 Millions
Sanara Medtech Inc	8.60	$ 106.873 Millions	$ 12.423 Millions
Protalix Biotherapeutics inc	8.57	$ 76.381 Millions	$ 8.912 Millions
Adapthealth Corp	8.55	$ 3,286.774 Millions	$ 384.194 Millions
Perrigo Company Plc	8.52	$ 4,177.500 Millions	$ 490.200 Millions

Date modified: 2026-08-30T15:05:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.